Influence of landiolol on peak flow in patients with chronic obstructive pulmonary disease

Influence of landiolol on peak flow in patients with chronic obstructive pulmonary disease - Influence of landiolol on peak flow in patients with chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020432

Enrollment

Registered

2016-03-01

Start date

2016-03-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with choronic obstructive pulmonary disease who are suspected coronary artery disease

Interventions

spirometer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: (a) Severe heart failure (HYHA class III or IV) (b)Systolic blood pressure <100mmHg (c) RR interval >240ms (d) AV block of grade II or III (e) Heart rate <60 beats/min. (f)Patients receiving oral beta blockers (g) LV dysfunction (EF<30%) (h)Patients having allergy to landiolol (i)Pregnant, breastfeed, or possibly pregnant women (j)Diabetic ketoacidosis or metabolic acidosis (k)Patients after coronary stent implantation (l)Patients having pacemaker of ICD (m)Patients who are considered inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Change in peak flow and forced expiratory volume% in 1 second	—

Countries

Japan

Contacts

Public ContactToru Miyoshi

Okayama University Hospital Cardiovascular Medicine

miyoshit@cc.okayama-u.ac.jp086-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026